Immuron logo

IMC - Immuron Share Price

A$0.145 0.0  3.6%

Last Trade - 06/12/19

Sector
Healthcare
Size
Micro Cap
Market Cap £12.3m
Enterprise Value £9.63m
Revenue £1.52m
Position in Universe 1118th / 1829
Bullish
Bearish
Unlock IMC Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

IMC Revenue Unlock IMC Revenue

Net Income

IMC Net Income Unlock IMC Revenue

Normalised EPS

IMC Normalised EPS Unlock IMC Revenue

PE Ratio Range

IMC PE Ratio Range Unlock IMC Revenue

Dividend Yield Range

IMC Dividend Yield Range Unlock IMC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IMC EPS Forecasts Unlock IMC Revenue
Profile Summary

Immuron Limited is a biopharmaceutical company. The Company focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The Company has three segments: Research and Development (R&D), HyperImmune Products and Corporate. The R&D segment focuses on the Company's research and development projects performed in Australia and Israel. The Company sells and licenses its product, Travelan. The HyperImmune Products segment is engaged in its Travelan product's activities, which occur in Australia, New Zealand and Canada. The Corporate segment's activities primarily occur in Australia. It also develops products for applications, including non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and clostridium difficile (C-Diff), diabetes, colitis and uropathogenic escherichia coli (UPEC). The Company also offers Protectyn, IMM 124-E-NASH and IMM 529-CDI.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated January 13, 1994
Public Since April 30, 1999
No. of Shareholders: 1,870
No. of Employees: 25
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 163,215,706
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address L 3 62 Lygon St, MELBOURNE, 3053, Australia
Web https://www.immuron.com.au
Phone +61 3 98245254
Contact ()
Auditors Grant Thornton Audit Pty Ltd
IMC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to IMC
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.